NCT01439399

Brief Summary

The aim of the present study is to evaluate the analgesic benefit of intravenous lidocaine and ketamine in the perioperative period of abdominal surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at below P25 for not_applicable postoperative-pain

Timeline
Completed

Started Dec 2005

Typical duration for not_applicable postoperative-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2005

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2007

Completed
4.2 years until next milestone

First Submitted

Initial submission to the registry

September 20, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 23, 2011

Completed
Last Updated

September 23, 2011

Status Verified

September 1, 2011

Enrollment Period

1.6 years

First QC Date

September 20, 2011

Last Update Submit

September 21, 2011

Conditions

Keywords

postoperative painpostoperative careintravenous lidocaineintravenous ketaminemorphine consumption

Outcome Measures

Primary Outcomes (1)

  • Cumulative morphine consumption

    Cumulative morphine consumption over 48 hours postoperatively

    48 hours

Secondary Outcomes (3)

  • Pain scores

    48 hours

  • Mechanical hyperalgesia

    48 hours

  • Occurrence of side effects

    48 hours

Study Arms (4)

Lidocaine

ACTIVE COMPARATOR

Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours

Drug: Lidocaine,

Ketamine

ACTIVE COMPARATOR

Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours

Drug: Ketamine

Ketamine-Lidocaine

ACTIVE COMPARATOR

Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.

Drug: association ketamine-lidocaine

Saline 0,9%

PLACEBO COMPARATOR

Control group

Drug: Placebo

Interventions

Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.

Lidocaine

Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.

Ketamine

Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.

Ketamine-Lidocaine

The control group (C) received an equal volume of saline 0.9 % during 48 h.

Saline 0,9%

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • abdominal surgery by laparotomy

You may not qualify if:

  • laparoscopy
  • history of chronic pain
  • opioid self-administration
  • psychiatric disorders
  • difficulties with communication
  • renal or hepatic dysfunction
  • ASA physical status \> 3

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Center and University

Lausanne, Canton of Vaud, CH-1011, Switzerland

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

LidocaineKetamine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbons

Study Officials

  • Christian Kern

    University of Lausanne Hospitals

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Resident

Study Record Dates

First Submitted

September 20, 2011

First Posted

September 23, 2011

Study Start

December 1, 2005

Primary Completion

July 1, 2007

Study Completion

July 1, 2007

Last Updated

September 23, 2011

Record last verified: 2011-09

Locations